- Last week European drugs regulators approved daily anti hair loss pill
- The National Institute for Health and Care Excellence is assessing the drug
Adults and teens with the severe hair loss condition alopecia areata could soon be offered a breakthrough medicine that can trigger regrowth in just six months.
Last week, European drugs regulators approved ritlecitinib, and it is currently being assessed by NHS spending watchdog, the National Institute for Health and Care Excellence (NICE).
Alopecia areata is one of the more common causes of hair loss and usually begins in childhood or early adulthood. It is caused by the body’s immune system attacking hair follicles and is characterized by patches of baldness.
But ritlecitinib has been found to reverse the condition in one in five patients.
There are approximately 100,000 alopecia areata sufferers in the UK, with experts believing the condition may be caused by genetics.
Jada Pinkett Smith, pictured, suffers from Alopecia areata, a common hair loss condition which affects 100,000 Britons
Denial of responsibility! Vigour Times is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
Denial of responsibility! Vigour Times is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
